UNRESECTABLE GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Clinical trials for UNRESECTABLE GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for UNRESECTABLE GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy targets Hard-to-Treat stomach cancer
Disease control CompletedThis early-phase trial is testing whether adding the immunotherapy drug pembrolizumab to standard chemoradiotherapy can help control gastroesophageal cancer that cannot be removed by surgery. The study includes 16 participants and primarily looks at safety and whether the cancer …
Matched conditions: UNRESECTABLE GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New drug combo shows promise for tough stomach cancers
Disease control CompletedThis study tested two drugs, olaparib and ramucirumab, in 51 people with advanced stomach or gastroesophageal junction cancer that had spread or could not be removed. The goal was to find the best dose and see how well the combination worked. The trial is complete, and results ma…
Matched conditions: UNRESECTABLE GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC